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Pere Barba,1,7 Jose Luis Pi~nana,1,8 Francesc Fernandez-Aviles,2 Jose Antonio Perez-Simon,3
Rodrigo Martino,1 Eva Lopez-Guerrero,4 David Valcarcel,1,7 Montserrat Rovira,2
Silvana Novelli,1 Isabel Campos-Varela,5 Lucıa Lopez-Anglada,3 Xavier Vidal,6
Lucıa Lopez Corral,3 Enric Carreras,2 Jorge Sierra1Liver dysfunction is frequent before allogeneic stem cell transplantation (allo-SCT). However, its character-
istics and impact on transplantation outcomes are uncertain, especially in the reduced-intensity conditioning
(RIC) setting. We analyzed 455 patients receiving an allo-SCT in 3 Spanish centers. Pretransplantation aspar-
tate aminotransferase (AST), alanine aminotransaminase (ALT), gamma-glutamyl transpeptidase (GGT), alka-
line phosphatase (AP), total bilirubin, and international normalized ratio were analyzed. Pretransplantation
liver function test abnormalities were found in 94 (22%) patients. The most frequent cause of pretransplan-
tation liver dysfunction was isolated elevation of GGT/AP (n 5 49, 53%). Patients with high bilirubin levels
before allo-SCT showed higher 4-year nonrelapse mortality (4y-NRM) (hazard ratio [HR] 2 [95% confidence
interval [CI] 1.1-3.8] P 5 .02) and patients with high GGT levels showed higher 100-day NRM and lower 4-
year overall survival (OS) (HR 3.4 [95% CI 1.8-6.7] P\.001, and HR 2 [95% CI 1.4-3], P5.001), respectively.
High levels of transaminases did not influence on survival or mortality. In conclusion, hepatic dysfunction be-
fore allo-SCT is frequent and has an impact on transplantation outcomes. The best indicator of liver dysfunc-
tion still has to be determined.
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Pretransplantation comorbidities are known tohave
a major impact on the outcome of allogeneic stem cell
transplantation (allo-SCT). In order to estimate the
potential risk of the procedure before transplantation,
several pretransplantation predictive models based
on comorbidities have been developed and validated
[1-3] in several disease and transplantation settings.
Recipients of reduced-intensity conditioning allo-
SCT (allo-RIC) are prone to have more significant co-
morbidities [4,5] because thesepatients areusually older
and have received several prior treatments. Thus, the
study of comorbidities in this group of patients is of
utmost importance.
Hepatic dysfunction before transplantation has
been identified as one of the most frequent comorbid-
ities in allo-SCT recipients [2,6,7] and included in
several comorbidity indexes. For instance, the
Hematopoietic Cell Transplantation comorbidity
index (HCT-CI) includes 2 items regarding hepatic
dysfunction: mild/moderate hepatic disease and severe
hepatic disease. Furthermore, the category of severe1653
1654 Biol Blood Marrow Transplant 17:1653-1661, 2011P. Barba et al.hepatic dysfunction was associated with the highest
hazard ratio for 2-year nonrelapse mortality (NRM)
among all the comorbid conditions included in the
development set of the HCT-CI [2].
Clinical data together with radiologic and labora-
tory tests are used in current practice to evaluate
hepatic dysfunction before transplantation. The most
frequent laboratory parameters used include aspartate
aminotransferase (AST), alanine aminotransferase
(ALT), bilirubin, alkalin phosphatase (AP), gamma-
glutamyl transpeptidase (GGT), international random-
ized ratio (INR), and the albumin levels. Among these,
AST,ALTandbilirubin are themost commonlyconsid-
ered in clinical practice and in pretransplantation pre-
dictive models [2,3]. The clinical significance of each
liver function test abnormality before transplantation,
their impact on transplantation outcomes, and the best
way to determine pre-SCT liver dysfunction remain un-
explored.With these aims,we conducted a retrospective
study in a large cohort of allo-SCT recipients receiving
a remarkably homogeneous conditioning.PATIENTS AND METHODS
The study included consecutive adult patients who
received an allo-SCT in 3 large transplant centers in
Spain between February 1998 and December 2008:
Hospital de la Santa Creu i Sant Pau, Barcelona
(HSCSP), Hospital Clinic of Barcelona (HCB), and
Hospital Universitario of Salamanca (USAL). The
transplant protocols were approved by national and lo-
cal ethics committees, and patients gave written in-
formed consent for their inclusion in each protocol.Conditioning Regimen, HLATyping, Infectious
Prophylaxis, and GVHDAssessment and
Prophylaxis
The transplant protocol has been published else-
where [8-11]. Patients received RIC regimens as
described [12,13]. Despite some patients receiving
fludarabine in combination with oral busulfan at
10 mg/kg, pharmacokinectic dosage adjustment of
busulfan was performed to ensure a similar steady-
state concentration (range: 800-1000 ng/mL) [14] irre-
spective of the final dose administered. Thus, because
all patients were exposed to similar concentration of
busulfan, we included in the current study such condi-
tioning as a RIC regimen. In brief, conditioning regi-
men for all patients included fludarabine (150 mg/m2)
in combination with melphalan (70-140 mg/m2) (lym-
phoid malignancies and multiple myeloma), busulfan
8-10 mg/kg (myeloid malignancies), cyclophospha-
mide 120 mg/kg (solid malignancies), or low-dose
total body irridiation (TBI) 2Gy (chronic myeloid
leukemia).Regarding HLA typing, family donors were tested
for HLA-A, -B (low resolution), and DRB1 (high reso-
lution). Unrelated donors were tested for HLA-A, -B,
-C, -DRB1, -DQB1 (high resolution). Allelic high-res-
olution HLA typing was performed by means of
polymerase chain reaction-sequencing based typing
PCR-SBT, whereas low-intermediate resolution typ-
ing was performed using the PCR Sequence-Specific
Oligonucleotide Primed PCR-SSO method.
Graft-versus-host disease (GVHD) was diagnosed
based on histological and clinical findings. Severity of
acute GVHD (aGVHD) was graded according to the
modified Seattle criteria [15]. Evaluation and diagnosis
of chronic GVHD (cGVHD) were performed based
on established criteria [16] and, more recently, on
the National Institutes of Health (NIH) consensus cri-
teria [17]. GVHD prophylaxis (summarized in Table
1) included cyclosporine A (CsA) plus methotrexate
(MTX) or CsA plus mycophenolate mophetil
(MMF). CsA was started on day 27 at a dose adjusted
to blood levels (between 200 and 300 mg/mL).
MTX was administered on days 11, 13, and 16
(10 mg/m2, followed by folinic acid rescue). MMF
was started on day 0 (at least 10 hours after infusion
of progenitors) at a dose of 15 mg/kg every 8 hours
and continued until day 130. In vivo T cell depletion
with alemtuzumab or antithymocyte globulin (ATG)
was used in patients receiving a transplant from HLA
mismatched donors or in a few patients included in
clinical trials.
Acyclovir, fluconazole, and quinolones (ciprofloxa-
cin or norfloxacin) were administered from day21 and
until neutrophilic recovery as infectious prophylaxis.
Cytomegolovirus (CMV) infection screening for guid-
ing preemptive therapy was performed as described
elsewhere in detail [18]. Galactomanann Platelia as-
say (Bio-Rad Laboratories, Hercules, CA) in blood
samples was routinely performed since 2003 [19].Management and Evaluation of Liver Function
before SCT
All patients were tested for AST, ALT, total and
conjugated bilirubin, GGT, AP, INR, hepatitis B sur-
face antigen (HBsAg), hepatitis B core antibodies
(anti-HBc), and antibodies against hepatitis C virus
(HCV) and serum ferritin levels. Because albumin
levels might be influenced by disease status at trans-
plantation this test was not considered as a useful
marker of liver dysfunction. Patients with moderate
or severe abnormalities of these tests or patients with
clinical suspicion of hepatic disease underwent imag-
ing examinations and biopsy according to physician’s
criteria. Laboratory tests of liver function were per-
formed within 7 days before the beginning of the con-
ditioning regimen. Imaging studies, if needed, were
performed within 30 days before transplantation.
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investigator in each center. Patients with pretransplan-
tation liver abnormalities were also reviewed by a sec-
ond investigator and by a local hepatologist when
needed. Severe abnormal AST, ALT, AP, and GGT
were considered for levels before transplantation
higher than 2.5 times the upper normal limit (UNL),
following the NCI criteria, version 3.0 [20] and the
HCT-CI criteria. In the sameway, severe abnormal to-
tal bilirubin levels and INR prolongation were consid-
ered when they were higher than 1.5  UNL and
higher than the UNL, respectively. High ferritin levels
were considered when $1000 ng/mL. Other abnor-
malities below these thresholds were considered mild.
The severe hepatic disease category of the HCT-CI
was calculated for all patients as originally defined [2].
Classification of Liver Diseases before SCT
Pretransplantation underlying hepatic diseaseswere
reviewedby a local hepatologist and hematologist.Com-
pensated cirrhosis was defined by a previous diagnosis of
cirrhosis without episodes of encephalopathy, ascites,
or presence of varices. Drug induced liver injury (DILI)
was defined as abnormal liver function related to previ-
ous treatment and without any other plausible cause of
liver toxicity. Nonalcoholic steatohepatitis was defined in
patients with laboratory and imaging findings of steato-
hepatitis with mild or no alcohol intake. Isolated eleva-
tions of AST/ALT and GGT/AP were defined as
isolated transaminases or cholestaticmarkers abnormal-
ities not includible in any of other categories.Definition
of viral chronic hepatitiswas based on a known active viral
infection and liver test abnormalities in patients without
clinical or imaging or pathologic evidence of cirrhosis.
Alcoholic fatty liver or hepatitis was identified in alcohol
consumers (.30 g/day in men, 20 g/day in women)
with compatible liver test abnormalities and no other
plausible causesof liver dysfunction.Hepatic iron overload
was suspected in patients with biochemical serum test-
ing with indirect ironmarkers or radiologic (MRI) find-
ings and confirmed with genotype testing or
pathological measurement of iron deposits in the liver
if clinically indicated. Autoimmune hepatitis and primary
biliary cirrhosis were defined in patients with laboratory
and histologic findings of these entities.
No prophylactic treatment with ursodeoxycholic
acid was used in any of the 3 centers during the study
period.
End points and Statistical Analysis
The primary endpoint of the study was to deter-
mine the impact of pretransplantation liver test abnor-
malities on 4-year NRM and overall survival (OS).
Secondary endpoints were description of liver function
test abnormalities before transplant and determination
of their impact on GVHD.OS and NRM were defined as the time from day
0 of the transplantation to death from any cause and
death from any cause but relapse, respectively. Patients
who died before engraftment and before day 1100
were not considered eligible for aGVHD and cGVHD
analysis, respectively. The incidence of aGVHD,
cGVHD, NRM, and relapse were calculated using cu-
mulative incidence estimates, taking into account the
competing risk model [21,22]. The probability of OS
was estimated from the time of transplantation using
Kaplan-Meier curves [23] and compared using the l-
rank test. Comparison between baseline characteristics
of patients was performed using contingency tables and
by means of chi-square or Fishers exact t tests. Contin-
uous variables were compared by means of the Wil-
coxon rank sum test. Univariate Cox regression
model was used to estimate the impact of the different
pretransplantation variables on NRM and OS. The
multivariate analyisis (MVA) was performed taking
into account the competing risk structure. Pretrans-
plantation variables with a significance level of P # .1
in the univariate analysis (UVA) were included in the
MVAwhere a significance level ofP# .05was required.
Because only 5 (1%) of the patients had INR abnormal-
ities before SCT, this item was not included in the sta-
tistical analysis of risk factors. Variables included in the
MVA are listed inTable 2.Other variables tested in the
UVA included stem cell source, patient gender, CMV
status, conditioning regimen and underlying disease,
renal impairment, and ferritin levels.
All statistical analyses were performed using SPSS
version 17.0 (SPSS, Inc., Chicago, IL), with the excep-
tion of the cumulative incidence analyses, which were
performed with NCSS 2004 (Number Cruncher Sta-
tistical System, Kaysville, UT).RESULTS
Patient Characteristics
All 455 consecutive patients who received an
allo-SCT in one of the 3 centers between the study pe-
riod were included. HSCSP, USAL, and HCB con-
tributed with 230, 145, and 80 patients, respectively.
Patients from each center were comparable in terms
of age, sex, underlying disease, risk disease status at
SCT, CMV serostatus, donor type, and conditioning
regimen (details not shown). Regarding the GVHD
prophylaxis regimen used, patients in USAL received
more CsA-MTX (n 5 125, 86%) compared with
HSCSP (n 5 146, 64%) and HCB (n 5 48, 60%),
P 5 .01. Consequently, the combination of CsA and
MMF was more frequently used in HSCSP (n 5 131,
29%) and HCB (n5 25, 31%) than in USAL (n5 11,
8%), P 5 .01). All the patients were grouped because
we previously reported that the use of MMF versus
MTX led to similar outcomes [24].
Table 1. Patient Characteristics and Transplantation
Outcomes
Patients 5 455
Median age, years (range) 53 (16-71)
Gender male, n (%) 276 (61)
Female donor to male recipient 118 (26)
Underlying disease, n (%)
AL or MDS-MPS 179 (39)
Hodgkin’s lymphoma 59 (13)
NHL and CLL 129 (29)
Multiple myeloma 72 (16)
Others 14 (3)
High-risk disease at HSCT,* n (%) 286 (63)
Recipient/donor CMV serology, n (%)
Recipient and donor negative 51 (11)
Recipient and/or donor positive 404 (89)
Donor type, n (%)
HLA identical sibling 363 (80)
Alternative† (VUD or MM related) 92 (20)
Conditioning regimen, n (%)
Fludarabine-Melphalan 276 (60)
Fludarabine-Busulphan 151 (33)
Other 28 (6)
T cell depletion, n (%) 62 (14)
Peripheral blood stem cells, n (%) 434 (95)
GVHD prophylaxis, n (%)
CsA-MTX 296 (65)
CsA-MMF 131 (29)
Transplantation outcomes
Cum. Inc. acute GVHD II-IV, % (95% CI) 26 (22-30)
Cum. Inc. chronic GVHD at 4 years, % (95% CI) 51 (46-57)
Cum. Inc. relapse at 4 years, % (95% CI) 32 (28-36)
Cum. Inc. NRM at 4 years, % (95% CI) 30 (26-35)
Probability of 4-year overall survival, % (95% CI) 48 (45-51)
Median follow-up for survivors, months (range) 53 (3-123)
AL indicates acute leukemia; MDS, myelodysplastic syndrome; MPS, mye-
loproliferative syndrome; NHL, Non-Hodgkin lymphoma; CLL, chronic
lymphocytic leukemia; n, number; HSCT, hematopoietic stem cell trans-
plantation; CsA, cyclosporine A; MTX, methotrexate; MMF, mycopheno-
late ofmophetil; GVHD, graft-versus-host disease;CI, confidence interval;
Cum. Inc., cumulative incidence; CMV, cytomegalovirus; VUD, volunteer
unrelated donor; MM, HLA mismatch; ATG, antithymocyte globulin.
*High-risk disease status was considered in patients with acute leukemia
in equal to or greater than second complete remission (CR), myelopro-
liferative disease in equal to or greater than second chronic phase and in
accelerated or blast phase, Hodgkin’s disease in equal to or greater than
third remission or with partial remission (PR), follicular lymphoma equal
to or greater than third CR, or large B cell lymphoma or multiple mye-
loma equal to greater than second CR or PR and solid tumors. Patients
with PR or persistent disease at transplantation (except for myeloma)
were also considered as advanced disease.
†Alternative donors include all donors except for HLA identical siblings.
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Table 1. A total of 363 (80%) received a transplant
from an HLA identical sibling, whereas 92 patients
were transplanted from alternative donors (5 [1%]
HLAmismatched relateddonors, 47 [10%]matchedun-
related donors, and 40 [9%] mismatched unrelated do-
nors). The median times of follow-up for all patients
and for survivors were 22 and 53 months, respectively.
No differences were observed between patients with or
without at least 1 severe liver test abnormality before
SCT regarding age, gender, baseline disease, condition-
ing regimen, GVHD prophylaxis, use of T cell deple-
tion, type of donor, CMV serostatus, and sex mismatch
between donor and recipient (details not shown).Hepatic Disease and Liver Test Abnormalities
before Transplantation
Severe abnormal levels of AST,ALT, total bilirubin,
GGT, AP, and INR were found in 10 (2%), 21 (5%),
22 (5%), 31 (7%), 40 (9%), and 5 (1%) patients, respec-
tively. Median levels of AST, ALT, total bilirubin,
GGT, AP, and the INR were 22 U/L (range: 7-289),
26 U/L (range: 3-565), 10 mmol/L (range: 2-287), 29
U/L (range: 4-768), 114 U/L (range: 5-1183), and 1.03
(range: 1.8-0.87), respectively.
Overall, 94 patients (21%) had at least 1 severe liver
test abnormality before transplantation. Of them, 16
patients (17%) had signs or symptoms of hepatic dis-
ease, whereas 78 (83%) were asymptomatic. The
most frequent clinical features were jaundice (n 5 9,
56%), edemas because of hypoproteinemia (n 5 4,
25%), and bleeding disorders (n 5 3, 19%). Pretrans-
plantation underlying liver diseases are summarized
in Figure 1.Outcome
GVHD
Among the 448 (98%) patients eligible for
aGVHD analysis, 193 (42%) developed aGVHD,
for a cumulative incidence of 42% (95% confidence
interval [CI] 37-47). A total of 125 (27%) patients
had grade II-IV aGVHD for a cumulative incidence
of 26% (95% CI 22-30). Seventy-nine patients
(17%) presented hepatic aGVHDat diagnosis for a cu-
mulative incidence of hepatic aGVHD of 16% (95%
CI 11-20). In MVA, risk factors for the development
of grade II-IV aGVHD were high GGT levels before
transplantation (HR 2.7 [95% CI 1.6-4.4], P\ .001)
and alternative (non-HLA identical siblings) donors
(HR 2.1 [95% CI 1.1-3.9], P 5 .03) (Table 2). We
also performed an MVA for the occurrence of hepatic
involvement at the time of diagnosis of aGVHD. The
only factor associated with hepatic involvement at
diagnosis of aGVHD was high GGT levels before
transplantation (hazard ratio [HR] 4.9 [95% CI 2.2-
11], P\ .001).
Regarding cGVHD, 391 patients (86%) were eli-
gible for the analysis. A total of 197 (50%) patients de-
veloped cGVHD during follow-up for a cumulative
incidence of 51% (95% CI 46%-57%). In the MVA,
patients with high ALT levels before transplantation
showed a higher probability of developing cGVHD
(HR 2.7 [95% CI 1.5-4.8], P 5 .001). Other variables
associated with higher probability of cGVHD in the
MVA were age .60 years (HR 2.2 [95% CI 1.3-3.5],
P 5 .002), alternative donors (HR 2.2 [95% CI 1.3-
3.5], P 5 .002), high-risk disease at SCT (HR 1.6
[95% CI 1.1-2.3], P 5 .009), and female donors to
male recipients (HR 1.6 [95% CI 1.2-2.2], P 5 .003)
(Table 2).
Table 2. Univariate and Multivariate Analysis of Pretransplant Hepatic Dysfunction and Other Risk Factors on Transplantation
Outcomes
Uni p 100-day NRM P Uni p 4-year NRM P Uni p 4-year OS P Uni p aGVHD II-IV P Uni p cGVHD P
ASTelevation
>2.5  UNL 0.1 — 0.5 — 0.7 — 0.15 — 0.2 —
ALTelevation
>2.5  UNL 0.1 — 0.6 — 0.1 — 0.5 — 0.001 2.7 (1.5-4.8) .001
Bil elevation
>1.5  UNL 0.001 3.1 (1.4-6.6) .004 0.03 2 (1.1-3.8) .03 0.2 — 0.5 — 0.2 —
GGTelevation
>2.5  ULN <0.001 3.4 (1.8-6.3) <.001 0.02 — ns <0.001 2 (1.4-3) .001 <0.001 2.7 (1.6-4.4) <.001 0.6 —
AP elevation
> 2.5  ULN 0.1 — 0.8 — 0.4 — 0.5 — 0.07 ns
Donor
Alternative 0.05 — ns 0.009 2.1 (1.4-3.1) .001 0.04 1.6 (1.2-2.3) .004 0.04 2.1 (1.1-4.9) .03 <0.001 2.2 (1.3-3.5) .002
Disease
High-risk 0.006 1.5 (1.1-2.1) .01 ns — ns — ns — <0.001 1.6 (1.1-2.3) .009
Age
$60 years ns — 0.007 2.1 (1.4-3.1) <.001 0.03 1.6 (1.2-2.2) .003 ns — <0.001 2.2 (1.3-3.5) .002
GVHD prof.
CsA-MMF ns — 0.002 nt* 0.009 nt* ns — 0.001 nt*
Female to male
Yes ns — ns — 0.03 1.4 (1-1.8) .04 ns — 0.003 1.6 (1.2-2.2) .003
TCD
Yes ns — ns — ns — 0.04 nt* 0.001 nt*
uni p indicates univariate analysis p value; AST, aspartate aminotransferase; UNL, upper normal limit; ALT, alanine aminotransaminase; GGT, gamma glu-
tamyl transpeptidase; AP, alkaline phosphatase; Bil, total bilirubin; PT, prothrombin time; NRM, nonrelapse mortality; OS, overall survival; GVHD, graft-
versus-host disease; aGVHD, acute GVHD; cGVHD, chronic GVHD; CsA cyclosporine A; MMF, mycophenolate of mophetil; TCD, T cell depletion; nt,
not tested; ns, nonsignificant; prof, prophylaxis.
*Variables not tested in the MVA because they showed colinearity with other variables in the analysis. Other variables tested in the UVA included stem
cell source, patient gender, CMV status, conditioning regimen, underlying disease, and severe renal impairment according to the HCT-CI criteria and
ferritin levels $1000 ng/mL. These variables did not show a significance level of P # .1 for any of the transplantation outcomes.
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Weanalyzed both early (100 days) and lateNRM(4
years) (Table 2). Concerning early NRM, the cumula-
tive incidence for the whole group was 11% (95% CI
9-15). Risk factors for 100-day NRM in the MVA
were high bilirubin (HR 3.1 [95% CI 1.4-6.6], P 5
.004), high GGT levels (HR 3.4 [95% CI 1.8-6.3], P
\ .001), and high-risk disease at SCT (HR 1.5 [95%
CI 1.1-2.1], P 5 .01). Cumulative incidence of late
NRM for all patients was 30% (95% CI 26-35). Pa-
tients with high bilirubin and GGT levels also showed
higher 4-year NRM in the UVA, but only the former
remain significant in the MVA (HR 2 [95% CI 1.1-
3.8], P 5 .03), whereas GGT showed a trend (HR 1.6
[95% CI 0.9-2.3], P 5 .09). Other risk factors for 4-
year NRM in the MVA were age at transplantation
.60 years (HR 2.1 [95% CI 1.4-3.1], P\ .001) and al-
ternative donors (HR 2.1 [95% CI 1.4-3.1], P\ .001).
Patients with and without renal impairment and high
ferritin levels before transplantation showed similar
NRM and OS.
To confirm the independent predictive role of
GGT and bilirubin levels, we excluded a possible co-
linearity between them. A total of 398 patients (88%)
had mild or normal GGT and bilirubin levels. High
GGT and mild or normal bilirubin levels were found
in 35 patients (8%), whereas the opposite was detected
in 18 patients (4%). Only 4 patients (1%) had both
high GGT and bilirubin levels (P 5 .12).
Forty-three (9%) patients were considered to have
severe hepatic disease according to the HCT-CI crite-ria. Patients with severe hepatic disease showed higher
NRM (HR 1.9 [95% CI 1.1-3.1], P 5 .01) but similar
OS (HR 1.4 [95%CI 0.9-2.2], P5 .1) than those with-
out (Figure 2).
A total of 133 patients (29%) experienced NRM
during follow-up. Morality causes were available for
128 patients (96%). The most common causes of
NRM were GVHD and infections (49 patients died
fromGVHDwith infection, 44 from infection without
GVHD, and 26 from GVHD without infection). Four
patients died because of severe hepatic disease not re-
lated to GVHD or infections. Among them, 2 patients
died because of venooclusive disease, 1 because of toxic
hepatitis related to cyclophosphamide-based condi-
tioning, and 1 because of late unexplained severe he-
patic insufficiency (necropsy was not performed).
Other causes of NRM included renal microangiopathy
(n 5 2), stroke (n 5 2), and suicide (n 5 1).
The probability of OS at 4 years for all patients
was 48% (95% CI 45-51). In the MVA, the factors
associated with lower OS were: high GGT levels
(HR 2 [95% CI 1.4-3], P \ .001), alternative do-
nors (HR 1.6 [95% CI 1.2-2.3], P 5 .004), older
patients (HR 1.6 [95% CI 1.2-2.2], P 5 .003),
and male recipients from female donors (HR 1.4
[95% CI 1-1.8], P 5 .04).
We analyzed the impact of the dose of busulfan on
transplantation outcomes. Among 151 patients receiv-
ing fludarabine and busulfan as conditioning regimen,
19 patients received busulfan at 8 mg/kg, whereas 132
received 10 mg/kg. Patients receiving busulfan at 10
11 (12%)
14 (15%)
1 (1%)
49 (52%)
7 (7%)
7 (7%)
4 (4%)
1 (1%)
Compensated chirrosis
DILI
NASH
Isolated AST/ALT elevation
Isolated GGT/AP elevation
Viral chronic hepatitis
alcoholic fatty liver or
hepatitis
iron overload
Figure 1. Pretransplantation hepatic underlying diseases in patients with abnormal pretransplantation liver function tests. Causes of pretransplantation
hepatic disease in the 94 patients who presented at least 1 severe liver test abnormality before transplantation. Numbers in the figures represent the
total number of patients and the prevalence of each category (%). Abbreviations: DILI, drug-induced liver injury; NASH, nonalcoholic steatohepatitis;
AST, aspartate aminotransferase; ALT, alanine aminotransaminase; GGT, gamma glutamyl transpeptidase; AP, alkaline phosphatase.
1658 Biol Blood Marrow Transplant 17:1653-1661, 2011P. Barba et al.mg/kg were younger than patients receiving 8 mg/kg
(median age 53 years [range: 18-69] versus 65 years
[range: 61-70], P\ .001). Patients receiving busulfan
at 8 mg/kg and 10 mg/kg showed similar 4y-NRM
(HR 1.1 [95% CI 0.7-1.8], P 5 .7) and OS (HR 0.9
[95% CI 0.7-1.3], P 5 .6). Furthermore, when com-
pared with all other patients in the cohort, patients re-
ceiving busulfan at 10 mg/kg also showed similar
NRM and OS (details not shown).
Relapse
Cumulative incidence of relapse at 4 years was
32% (95% CI 28-36). Relapse rates were not different
between patients with and without severe hepatic ab-
normalities before transplantation (HR 1.1 [95% CI
0.7-1.7], P 5 .6).DISCUSSION
The present study describes the incidence and
characteristics of hepatic dysfunction before trans-
plantation and analyzes the impact of each liver test ab-
normality on transplantation outcomes in a relatively
homogeneous cohort of allo-SCT recipients. To our
knowledge, this is the largest study regarding hepatic
dysfunction before allo-SCT and its impact on trans-
plantation outcomes.
Overall, 94 (21%) patients had at least 1 liver test
abnormality before transplantation. The most fre-
quent liver test abnormalities were high GGT and
AP levels. INR abnormalities were found in only
5 (1%) patients, probably because coagulation abnor-
malities appear in a final stage of liver disease and pa-
tients in this condition are usually not considered for
allo-SCT. According to the HCT-CI criteria, 43 pa-
tients (9%) were included in the severe hepatic diseasecategory, which was similar to the reported preva-
lences in other studies using the same criteria, which
ranged between 4% and 16% of the patients [2,5,25].
The current study highlights that high AST, ALT,
and AP levels had no apparent impact on transplanta-
tion outcome. On the contrary, bilirubin and GGT
levels showed deleterious effects in this cohort of unse-
lected allo-RIC recipients. These results led us to sev-
eral conclusions.
First, AST and ALT levels before transplantation
were not useful in predicting mortality and survival af-
ter the procedure in our patients. AST and ALT are
sensitive indicators of liver-cell injury and are helpful
in determining hepatocellular damage. AST is pro-
duced in several organs such as the liver, cardiacmuscle,
and the kidneys. ALT is thought to be more specific
than AST because it is present mainly in the cytosol
of the liver and in very low concentrations elsewhere
[26]. These enzymes are routinely used in clinical prac-
tice to evaluate liver function before SCT. However,
very few studies have evaluated the impact of pretrans-
plantation transaminases on the outcome of the proce-
dure. In contrast with our findings, other groups have
identified pretransplantation levels of ALT and AST
as a risk factor for survival after allo-SCT [3,27].
Because of this controversy, we think that the
elucidation of the predictive role of transaminases in
the allo-SCT setting requires further studies.
Second, the bilirubin level was a strong predictor of
mortality in our series. Bilirubin has also been used to
predict outcome in solid organ transplantation [28]
and other settings such as colorectal cancer [29]. In
light of our results, we support the use of bilirubin in
the pretransplantation evaluation of SCT candidates.
Third, in our patients, GGT levels seemed to be
related with worse outcome of the procedure. GGT
p=0.01 p=0.1 
Overall Survival 
Figure 2. Impact of pretransplantation hepatic dysfunction on transplantation outcomes. Impact of the HCT-CI criteria for severe hepatic disease on
NRM (A) and OS (B). Dashed lines indicate severe abnormalities of liver function tests; continuous lines indicate normal or mild liver function tests,
according to the original definition of the HCT-CI.
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hepatocytes and biliary epithelial cells. In clinical prac-
tice, GGT is thought to be a hypersensitive marker of
hepatic disease and its usefulness is sometimes consid-
ered limited by its lack of specificity [30]. However, re-
cent epidemiologic prospective studies showed that
serum GGT predicted the appearance of several dis-
eases and mortality from all causes in different popula-
tions [31-34]. Recently, Ruhl and Everhart performed
a death certificate–based study among 14,950 patients
in the United States. They found an association be-
tween elevated GGT and mortality from all causes,
liver disease, cancer, and diabetes, whereas ALT was
only associated with liver disease mortality [34]. Bio-
logic mechanisms explaining these findings are not
clear. Some have suggested that serum GGT might
be an early marker of oxidative stress because cellular
GGT is linked to metabolism of glutathione (GSH),
the most abundant intracellular antioxidant [35]. An-
other explanation is that serumGGTmight act as a cu-
mulative biomarker of various environmental toxics,
because GSH is critical to conjugate chemicals [36].
To our knowledge, this is the first study demonstrating
that high levels of GGT might be an independent risk
factor for mortality and survival in allo-SCT recipi-
ents. In view of our results, we think that GGT should
be taken into account when evaluating liver function
before transplantation. However, its impact on trans-
plantation outcomes should be validated by other
groups and in other transplant settings.
Regarding GVHD, the only hepatic variables asso-
ciated with higher occurrences were high GGT levels
for aGVHD and high ALT levels for cGVHD. The
production of free radicals and oxidative stress have
been identified as physiopathologic phenomena of
aGVHD in vitro [37]. The aforementioned association
amongGGT,GSH, and oxidative stressmight partiallyexplain the higher occurrence of aGVHD in patients
withhighGGTlevels, but further studies should beper-
formed to confirm this hypothesis. Concerning
cGVHD, these results have to be taken with caution
for several reasons. First, 14 (36%) and 8 (36%) patients
withhigh levelsofGGTandbilirubin, respectively, died
before day1100 andwere not evaluable for the analysis
of cGVHD. Thus, the impact of these 2 markers on
cGVHD might have been underestimated because of
low number of patients. Second, data about the specific
organ involvement of cGVHD was unfortunately not
available. We cannot exclude that ALT predicted only
hepatic cGVHD but no other organ’s involvement. As
in aGVHD, more research is mandatory to clarify the
impact of hepatic dysfunction on cGVHD.
Pretransplantation predictive models, including
hepatic dysfunction, use a wide range of definitions of
this condition. For the HCT-CI, patients with severe
hepatic disease showed higher 4y-NRM but similar
OS than patients withmild or no hepatic disease before
SCT. Because patients with high bilirubin levels alone
showed similar results (Table 2), we cannot exclude
that the predictive capacity of theHCT-CI liver disease
category in our patients may have been limited to bili-
rubin levels, whereas transaminases would have had lit-
tle effect. However, because others have shown the
impact of transaminases [3,27] on transplantation
outcomes, we consider that further research is
necessary to determine the best indicators of liver
dysfunction to be included in the comorbidity indexes.
One of the main limitations of this study is that not
all comorbid conditions in the HCT-CI were included
in theMVAbecause of insufficient data in thedatabases.
Thus, we cannot completely exclude that patients
with abnormal liver function also had other organ
dysfunctions.However, we performed a subgroup anal-
ysis of 194 consecutive patients from one center with
1660 Biol Blood Marrow Transplant 17:1653-1661, 2011P. Barba et al.available data of all comorbid conditions included in the
HCT-CI (published recently) [7]. In these patients, the
impact of the severe hepatic disease category of the
HCT-CI remained significant in the MVA including
all other comorbidities (details not shown). Thus, at
least in this subgroupof patients, the impact of liver dys-
functionwasnot dependent on thepresenceof other co-
morbidities. Other limitations of the present study are
derived from its retrospective nature.
Finally, the results of the present study and of other
reports, such as the development of pretransplantation
predictive models of mortality (HCT-CI and PAM
score, for example), argue in favor of creating future
strategies to adapt the transplantation procedure to
high-risk patients based on pretransplantation charac-
teristics. However, the translation of all these findings
into clinical practice appears as a great challenge for cli-
nicians and investigators. Some efforts have been made
in this direction including the use of defibrotide,N-ace-
tyl-L-cysteine, ursodeoxycholic acid, and heparin to
prevent some hepatic complications after SCT, such as
veno-occlusion disease (VOD) [38-41]. Development
of pharmacogenetic studies in high-risk patients or the
reduction in dosage of hepatotoxic drugs in patients
with abnormal liver function before transplantation
may appear as clinical options [42,43]. From our
perspective and based on the reported evidence,
we think that the combination of prophylactic
ursodeoxycholic acid and a careful management of
hepatotoxic drugs would be a reasonable prevention
strategy in patients with pretransplantation abnormal
liver function. However, the usefulness of these
strategies should be assessed in clinical trials.
In conclusion, pretransplantation hepatic dysfunc-
tion has an impact on the outcome of allo-SCT, but
the best indicator of liver dysfunction before allo-
SCT is still unclear. However, in light of our results,
we feel that GGT and bilirubin should be considered
in the future predictive models.ACKNOWLEDGMENTS
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